While further studies are warranted to explore additional regulatory mechanisms, our results provide strong evidence that targeting de novo lipogenesis through PI3K/AKT-SREBP1/FASN modulation represents a potential therapeutic approach for CRC. This evidence concerns the gene FASN and colorectal carcinoma.